Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2015 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress

Global Phase 3 Registration-enabling Studies on Track to Begin in Second Half of 2015 for AG-221 & First Half of 2016 for AG-120 Phase 1 Expansion Studies for AG-221 & AG-120 Programs...
August 05, 2015 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015

CAMBRIDGE, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the...
July 30, 2015 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Second Quarter 2015 Financial Results on August 6, 2015

CAMBRIDGE, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced...
June 24, 2015 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

– Third IDH Mutant Inhibitor to Enter Clinical Trials – – Brain Penetration and Pan-IDHm Inhibition Broaden Development Options for IDH Mutant-Positive Cancers, Including...
June 23, 2015 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Appoints Maykin Ho, Ph.D., to its Board of Directors

CAMBRIDGE, Mass., June 23, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced...
May 18, 2015 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Patients with Acute Myelogenous Leukemia with an IDH1 Mutation

CAMBRIDGE, Mass., May 18, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that...
May 07, 2015 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120

AG-221: Ongoing Phase 1 study expanded by an additional 125 patients in selected AML (acute myeloid leukemia) populations AG-120: Ongoing Phase 1 hematologic malignancy study expanded by 175...
April 29, 2015 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Selects Third Novel IDH Mutant Inhibitor, AG-881, for Clinical Development

- Brain-penetrant, pan-IDH mutant inhibitor broadens pipeline for treatment of patients with IDH mutant positive cancers - New worldwide development and profit share collaboration for AG-881...
April 28, 2015 16:05 ET | Source: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals to Webcast Conference Call of First Quarter 2015 Financial Results on May 7, 2015

CAMBRIDGE, Mass., April 28, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced...
March 24, 2015 15:04 ET | Source: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency

- PK deficiency is a severe and rare genetic disease with currently no approved or disease modifying treatments - CAMBRIDGE, Mass., March 24, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc....